You are here

eczema

OX40 inhibitors may shift the atopic dermatitis landscape

Clinical Trials Arena

Mon, 04/14/25 - 07:10 pm

atopic dermatitis

AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2

Fierce Biotech

Wed, 12/11/24 - 11:27 am

clinical trials

atopic dermatitis

TRex Bio raises $84M to compete in crowded immune drug field

BioPharma Dive

Wed, 11/13/24 - 10:51 am

FDA approves Eli Lilly's drug for eczema

Reuters

Mon, 09/16/24 - 10:16 pm

Lilly's lebrikizumab, delayed at FDA, clears eczema in people with skin of color

Fierce Biotech

Mon, 03/11/24 - 05:11 pm

Apogee data hint at potential for long-lasting eczema drug

BioPharma Dive

Tue, 03/5/24 - 11:33 am

Apogee Therapeutics

clinical trials

Eying Incyte's Opzelura, Leo Pharma shares data for JAK cream in hand eczema

Fierce Pharma

Sun, 10/15/23 - 11:52 pm

clinical trials

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

BioSpace

Mon, 10/2/23 - 10:36 am

atopic dermatitis

drug manufacturing

Sanofi's $1.1B eczema drug hits midphase goal, spurring talk of phase 3 and new indications

Fierce Biotech

Tue, 06/27/23 - 10:09 am

clinical trials

Aslan sells Japanese rights to would-be Dupixent rival for $12M

Fierce Biotech

Thu, 06/22/23 - 10:41 pm

Eli Lilly unveils new data from atopic dermatitis therapy trials

Clinical Trials Arena

Tue, 05/2/23 - 10:22 am

atopic dermatitis

Leo Pharma announces positive results for hand eczema study

Pharmaphorum

Mon, 02/13/23 - 10:23 am

clinical trials

chronic hand eczema

One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial

Endpoints

Tue, 11/15/22 - 06:35 pm

Arcutis Biotherapeutics

clinical trials

Despite recent progress, Incyte still far off from pricing goal for key eczema launch Opzelura

Fierce Pharma

Tue, 11/1/22 - 06:59 pm

Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out

Fierce Biotech

Tue, 11/1/22 - 12:09 pm

Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch

Fierce Pharma

Mon, 03/14/22 - 11:37 pm

Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data

Fierce Biotech

Wed, 02/2/22 - 10:59 am

atopic dermatitis

Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA

Fierce Pharma

Fri, 01/28/22 - 11:47 am

Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data

Endpoints

Fri, 12/17/21 - 10:52 am

Connect Biopharma

clinical trials

Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions

Fierce Pharma

Mon, 12/13/21 - 11:04 am

Pages